Compare D R Horton Inc (DHI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Novo Nordisk A/S — how do they compare? D R Horton Inc trades at $134.88 (market cap $37.99B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 4.4× D R Horton Inc's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Novo Nordisk A/S for 116 Days on average.
| DHI | NVO | |
|---|---|---|
Market Cap | $37.99B | $165.31B |
Volume | 2,974,460 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $63.98 |
52-Week Low | $132.53 | $35.29 |
Typical Hold Time | 46 Days | 116 Days |
Enterprise Value | $43.09B | $179.56B |
Dividend Yield | 1.33% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $135.82, up 1.91% with a bearish technical signal despite recent earnings beats. The stock faces headwinds from rising mortgage rates impacting the housing sector, with revenue declining to $34.25B in 2025 and net income margin compressing to 9.15%. Analyst consensus remains positive with a $156.57 price target, but technical indicators show resistance at $137 with support at $133.
The outlook is mixed with strong fundamentals and attractive valuation (P/E 12.95) offset by macroeconomic pressures on housing demand. Key risks include persistent high interest rates and housing market volatility, while institutional sentiment leans bullish with 47% buy ratings. The stock offers value for long-term investors but faces near-term sector headwinds.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.66, net margin of 35.35%, and consistent earnings beats. Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal expansion. Cash flow remains positive at $10.81B despite increased capital expenditures.
The outlook remains positive with 59% analyst buy ratings and a $44.67 price target representing 17% upside. Key risks include FDA delays for hemophilia drug denecimig and intensifying competition from Eli Lilly. Revenue growth continues at 6.6% annually with improving profitability margins supporting valuation expansion potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
